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Abstract Alternative medicine use has increased at a remarkable pace all over the world in recent years.
Although herbal medicine for the treatment of asthma is becoming the focus of public attention, randomized
studieshadnotbeenperformed, evenin Easterncountriesincluding Japan.This studywasdesignedto investigatewhether
one of the Japanese government approved herbal complexes Saiboku-to (TJ-96) is effective for the treatment of atopic
asthma, and to investigate whether this protective activity is associatedwith a reduction in eosinophilic inflammation. A
double-blind, randomized, crossoverdesignwasused.Subjectsreceived 2.5 gof TJ-96 orplacebo orally 3 timesdaily for 4
weeks andthen, after awashoutperiodof atleast 4weeks, crossedover toreceivethe alternativetreatment.Weassessed
the effects of pretreatment withTJ-96 on bronchoconstriction precipitated by inhalation of methacholine.Furthermore,
eosinophil counts andmeasurement of eosinophilic cationic protein (ECP) were performed. After 4 weeks of treatment
withTJ-96, valuesof PC20-methacholine significantlyimprovedinthetreatmentwithTJ-96.Also, patients’symptoms, blood
eosinophils, serum ECP, sputumeosinophils, and sputum ECPwere significantlydecreased.Ourresults suggestthat TJ-96
has an antiinflammatoryeffecton bronchial eosinophilic infiltration.This studyraises further interesting therapeutic pos-
sibilities and argues for further trials of newapproaches to the treatmentof asthma.r2002 Elsevier Science Ltd
doi:10.1053/rmed.2002.1307, available online athttp://www.idealibrary.comon
Keywords bronchial asthma; eosinophilic cationic protein;TJ-96 (‘‘Saiboku-to’’ or ‘‘Chai-pu-tang’’); bronchial eosinophilic
in£ammation.INTRODUCTION
Herbal therapy for the treatmentof asthma hasbeen es-
tablished long time ago in Japan. Since Japanese Ministry
of Health and Welfare o⁄cially approved traditional
herbs for medical use, the governmental health insur-
ance cover the cost of treatments with them. Surpris-
ingly, randomized studies had not been performed for
the approval, although the Japanese government author-
ized161complexes of traditional herb (1). Japanese herbal
medicine is called ‘‘Kampo’’, which was originated from
ancient China, modi¢ed and sophisticated in the history
of traditional Japanesemedicine.
In Japanese National Guidelines for the Management
of Asthma, six kinds of herbal complexes are included as
recommended therapy for the treatment of asthma (2).Received 30October 2001, accepted in revised form 8 January 2002.
Correspondence should be addressed to: Hideaki Amayasu,MD,
Hirosaki University School of Medicine, 8-1401Ichibancho,Hirosaki
036-8201Japan.Fax: +81-172-37-0423; E-mail: amayasu@nisiq.netEspecially,‘‘Saiboku-to’’ (‘‘Chai-pu-tang’’ in Chinese, TJ-96)
is one of the most popular herbal complexes for long-
time management of asthma. A previous study showed
that TJ-96 is e¡ective in reducingbronchial hyperrespon-
siveness and allergen-induced eosinophilic in¢ltration in
sensitized guinea pigs (3).The aims of the present study
were (1) to con¢rm these observations of TJ-96’s anti-
asthmatic activity and other e¡ects on bronchial eosino-
philic in¢ltration and (2) to examine whether the
protective activity of this drug against asthma is asso-
ciated with a reduction in the eosinophilic in£ammation
that contributes to the pathogenesis of asthma. A dou-
ble-blind, randomized, crossover designwas used.
MATERIALSANDMETHODS
Subjects
We studied 33 adult patients (15 males and 18 females;
ages, 4277 (SD) years; FEV1, 81.576.9 (SD) %pred.) with
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and serum IgE level. Allpatientswerenonsmokers (never
smokers only), neither were aspirin intolerant nor
COPD, and all had mild or moderate asthma diagnosed
according to the criteria of the AmericanThoracic So-
ciety (4). The patients were in stable condition and had
been free of symptoms of respiratory infection for at
least 6 weeks.
Patients using any herbal medicine includingTJ-96 be-
fore, oral or inhaled corticosteroids, any antileukotriene
drug, and chemical mediator inhibitor such as cromolyn
sodiumwere excluded. All patients used ametered-dose
inhaler ofb-stimulants ondemand and/or theophylline to
control their asthma.The study was conducted accord-
ing to the ethical standards of ourmedical center, which
require informed consent from each patient.
Study design
A double-blind, randomized, crossover design was used.
Subjects were randomly assigned to receive orally a 4-
week course of daily dose of 2.5 g of readymade freeze-
dried powdered Saiboku-toTJ-96 (Tsumura Co., Ltd., To-
kyo, Japan) or a dose of placebo that was identical in ap-
pearance and taste. After a washout period of at least 4
weeks, the subjects crossed over to receive the alterna-
tive treatment for 4 weeks.
FEV1, FVC, and methacholine provocation testing
were performed.Blood and induced-sputum, di¡erential
and total cell counts were determined before and after
each 4-week treatment course.
Blood count and serum eosinophilic cationic protein (ECP)
measurement
Blood samples for eosinophil counting andmeasurement
of ECP were taken between 8:00 and 9:00 a.m. on the
day of methacholine provocation testing (5). Blood was
collected in heparinized tubes by direct venipuncture,
and blood smears were made for di¡erential staining
(Di¡ quick; American Scienti¢c Products, McGawPark,
IL). Di¡erential cell counts were calculated as the mean
value of two slides, with 300 cells counted per slide.The
total leukocyte count was determined with a hemocyt-
ometer (Neubauer Chamber: Hausser Scienti¢c, Blue
Bell, PA), and cell populations were expressed as number
of cells permilliliter of blood.
To avoid interassay variations, all ECP measurements
were performed in the same run. Blood 4ml was col-
lected in an SST tube (BectonDickinson,MountainView,
CA), stored for 60min at 251C, and subsequently centri-
fuged at1300 g for10min at 41C. Serumwas stored at
801Cuntil ECP levels weremeasuredwith an ECP RIA
(radioimmunoassay) kit (Pharmacia Diagnostics, Uppsa-
la, Sweden).The detection limit of this assay is 2.0mg/l.Sputumanalysis
Sputum was induced and processed as described by Po-
pov et al. (5) Subjects inhaled 3, 4, and 5% saline for 7min
each.The inductionwas stoppedwhen an adequate sam-
ple was obtained or if the FEV1 dropped  20% from
baseline. Cell plugs with few or no squamous epithelial
cells were selected from the samplewith an invertedmi-
croscope, separated from saliva, and weighed. Samples
were aspirated in twice their volume of 0.1% dithiothrei-
tol (Sputolysin, Calbiochem Corp., San Diego, CA) and
twice their volume ofDulbecco’sphosphate-bu¡ered sal-
ine (DPBS; Gibco,Grand Island,NY).The cell suspension
was ¢ltered through nylon gauze (mesh size is 52mm;
BNSHThompson, Scarborough,ON,Canada) to remove
debris, then centrifuged at 1300 g for 10min at 41C.
Supernatants were collected and stored at 801C for
£uid-phasemeasurements of ECP.
The total cell count was determined with a hemocy-
tometer (Neubauer Chamber) and expressed as the
number of cells permilliliter of sputum.Cells were resus-
pended in DPBS at a concentration of 0.75^1.0106/ml.
Cell preparations for cytocentrifugation were made on
glass slides from 50ml of cell suspension and subjected
to cytocentrifuge (Shandon III, Shandon Southern Instru-
ments, Sewickey, PA), at 300 g for 5min. Di¡erential
cell counts were obtained from the mean of two slides
stainedwith Di¡ Quick with 400 cells counted per slide.
Cell types were quantitated as the number of cells per
milliliter of sputum.Cell preparations for cytocentrifuga-
tion were made on apex-coated slides and ¢xed for
10min in periodately sine^paraformaldehyde for immu-
nocytochemical staining for ECP.
Methacholine provocation testing
Bronchial responsivenesswas evaluatedbymethacholine
provocation according to the standardmethod of the Ja-
panese Society of Allergology (6,7) This test employed
methacholine chloride (Sigma, St. Louis, MO), dissolved
in saline to make solutions of 0.04, 0.08, 0.16, 0.31, 0.63,
1.25, 2.5, 5, 10, 20, 40, 80, and 160mg/ml administrated
by a jet nebulizer driven by compressed air (Nihon Shoji
Co., Ltd.Osaka, Japan).
All patients were given a provocation test after a 4-
week treatment coursewith eitherTJ-96 or placebo in a
double-blind, randomized manner. Thereafter subjects
were crossed over to receive alternative treatment, and
following an identical procedure at the same time of day.
To avoid the acute-phase e¡ect of TJ-96, each provoca-
tion testwas performedbefore takingTJ-96 in themorn-
ing. Each study day beganwithmeasurement of FEV1and
FVC for baseline, followedby inhalation of nebulized sal-
ine to rule out a nonspeci¢c obstructive reaction; FEV1
was measured 5min before and 5, 10, and 15min after
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10%, the subject entered themain part of study.
Methacholine was inhaled for 2min by tidal breathing
with a nose clip, immediately followed by spirometry.
Methacholine of increasing concentration was succes-
sively inhaled until FEV1 fell by 20% or more from base-
line. The measured values were plotted on
semilogarithmic graph paper, and themethacholine pro-
vocative concentration producing a 20% fall in the FEV1
was calculated as PC20-methacholine. The provocation
test was terminated by the administration of an inhaled
bronchodilator if FEV1 fell by more than 35% from base-
line. The higher of the ¢rst two satisfactory recordings
was taken for analysis.
Symptomscore
To evaluate the e¡ect of TJ-96 on the improvement of
symptoms in asthmatics, symptoms were assessed
weekly by physicians using four grades: 0=asymptomatic
more than 4 days/week; 1=mild symptom (aware of
symptoms but easily tolerated) more than 4 days/week
and nocturnal asthma symptoms less than 2 days/week;
2=moderate symptom (discomfort enough to interfere
with daily activity) more than 4 days/week and/or noc-
turnal asthma symptoms more than 2 days/week; and
3=severe attack (unable to perform usual activity) more
than 4 days/week and/or nocturnal asthma symptoms al-
most everyday.Thismethod ismodeled after that of Oo-
saki et al. (8).
Statistical analysis
Statistical evaluation employed StatView J-4.02 for Ma-
cintosh (Abacus Concepts, Inc., Berkeley, CA). All PC20
values were logarithmically transformedbefore analysis,
and summary statistics were, expressed as mean 7
standard deviation (SD). Student’s paired t-test was usedTABLE 1. Pulmonary function data and symptom scoresmeasu
with chronic asthma
Parameter Mean7SD of indicatedparameter
Placebo
Before After
FEV1 (L) 2.8870.14 2.897
%FEV1 81.076.0 82.17
FVC (L) 3.8870.24 3.847
%FVC 93.074.0 89.87
Symptom score 1.6670.43 1.637
Note: All valuesmarkedwith asteriskswere signi¢cantlygreateto compare mean di¡erences. Wilcoxon’s signed-rank
test was used for comparison of the two treatment
groups at the same time point regarding FEV1 and ECP
values. A P value less than or equal to 0.05 (two-sided)
was considered signi¢cant.
RESULTS
After the 4 weeks of treatment withTJ-96, none of the
subjects reported any adverse e¡ect, nor could they dis-
criminate between TJ-96 and placebo. The FEV1 was
slightly improved but not signi¢cant by administration of
TJ-96 after 4-weeks’each treatment (Table1).
Twenty-seven of the 32 subjects improved in general
symptoms, such as nocturnal cough, wheezing, and se-
verity or frequency of asthmatic attack,Other subjects
felt no change in their symptoms, since their conditions
were stable.No subjectgotworse thanbefore thebegin-
ning of this study. The symptom score signi¢cantly de-
creased after treatment with TJ-96 (Table 1, 0.7370.25
afterTJ-96 vs1.6970.39 after placebo, Po0.001).
Blood eosinophils, serum ECP, sputum eosinophils,
and sputum ECP were signi¢cantly decreased by TJ-96
(Table 2). On the other hand, the number of blood and
sputum neutrophils did not change signi¢cantly.
On methacholine provocation day, all subjects were
followed for longer than120min after provocation test.
After pretreatmentwithTJ-96 or placebo, challengewith
methacholine caused an obstructive reaction in all pa-
tients.Data for PC20 -methacholine in all patients aredis-
played in Fig. 1. In the provocation challenge with
methacholine, values of PC20 -methacholine signi¢cantly
improved afterTJ-96. Mean log PC20-methacholine was
2.9370.54 after TJ-96, vs 2.5270.55 after placebo
(Po0.01).
In the present study, after 4-weeks’ treatment with
eitherTJ-96 or placebo, there is no signi¢cant association
between the improvement of PC20 -methacholine andred before and after 4 week’s treatment withTJ-96 in patients
TJ-96
Before After
0.11 2.8570.13 3.0970.15
5.6 81.675.7 86.977.1
0.20 3.7870.29 3.8570.22
3.6 91.574.5 92.273.9
0.39 1.6570.38 0.7370.25*
r thanbaseline: *Po0.001baseline.
TABLE 2. Comparison of parametersmeasured before and after 4 week’s treatment with planrukast in patientswith chronic
asthma
Parameter Mean7SD of indicatedparameter
Placebo TJ-96
Before After Before After
Blood
Eosinophils (%) 9.575.3 9.374.9 9.874.8 5.372.5*
Neutrophils (%) 55.3716.7 56.3720.0 55.5719.6 53.2725.1
Serum ECP (mg/l) 16.076.2 15.877.3 15.677.6 3.771.4*
Sputum
Total cells (108/l) 19.871.3 19.672.8 19.272.9 17.270.9
Eosinophils (%) 12.976.6 13.878.2 13.977.7 5.374.5*
Neutrophils (%) 55.876.6 56.375.5 55.477.0 57.875.8
Lymphocytes (%) 24.873.4 23.974.6 22.574.9 28.575.5
Macrophages (%) 5.875.2 6.174.8 7.476.0 8.976.6
ECP (mg/l sputum) 7367315 7477318 7297326 180746*, **
Note: All valuesmarkedwith asteriskswere signi¢cantlygreater thanbaseline: *Po0.05, **Po0.001baseline
FIG. 1. Individualresults of PC20-methacholine at baseline and
after treatment withTJ-96 or placebo.Both results are shown as
themean, withthe bar indicating SD.All PC20 valueswere1ogar-
ithmically transformed before analysis, and summary statistics
were expressed asmean7SD.
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and the improvement of PC20 -methacholine. In addition,
Wilcoxon’s signed-rank test showedno signi¢cant corre-
lationbetween themaximum falls in FEV1or the concen-
tration of methacholine inhaled and the corresponding
maximum decrease in ECP values after placebo. All the
data for before placebo, after placebo, beforeTJ-96 were
not di¡erent signi¢cantly.DISCUSSION
Eosinophils are among themost important components
of bronchial in£ammation and bronchial hyperrespon-
siveness. Serum ECP is thought to be a useful marker of
eosinophilic in£ammation inbronchial asthma (9^12).Re-
lease of ECP and other granular proteinsmay contribute
to epithelial damage and in£ammation and thereby to an
increase inbronchial hyperresponsiveness. Also,ECP has
beenreported to elevatebronchoalveolar lavage £uid, to
play an active secretoryrole of the eosinophil in the late-
phase asthmatic reaction, and play an active role in the
late-phase asthmatic reaction (13). In this study, 4 weeks
of treatment with TJ-96 lowered the symptom scores
and decreasedbronchial responsiveness tomethacholine
inpatientswith atopic asthma, althoughneither FVCnor
FEV1 increased. Moreover, TJ-96 treatment decreased
both blood and sputum ECP levels as well as blood and
sputum eosinophil counts. Thus TJ-96 has an antiasth-
matic activity which is not associated with bronchodila-
tion butwith inhibition of eosinophilic in¢ltration.
Japanese traditional herbal therapy is so systemic, but
its theory is completely di¡erent from Western medi-
cine. Doctors who want to use herbal medicine should
learn how to evaluate patients’ conditions, and how to
choose the best herbal medicine for the improvement
of patients’ illness along with the theory of Oriental
medicine.They also have to distinguish patients whether
responders or nonresponders according to their exper-
tise before beginning herbal therapy. The fundamental
rules to choose appropriate herbal medicine are based
on patients’ constitution, predisposition, stamina, and
strength of response against illness. However, we did
not distinguish the patients according to the diagnosis
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study was a randomized controlled study.Our study re-
vealed that TJ-96 is signi¢cantlye¡ective for themanage-
ment of allergic asthma evenwithout the diagnosis along
with the theory of Orientalmedicine.
TJ-96 is one of the most useful non-steroidal thera-
peutic Kampo drugs for the treatment of asthma.
Although the inhibitory action of TJ-96 on antiasthmatic
activity is well documented, its mechanism are less well
de¢ned. Previous studies showed several pharmacologi-
cal e¡ects in vivo and in vitro. Tohda et al. reported that
TJ-96 inhibited both immediate asthmatic response and
late asthmatic response, in¢ltration of eosinophils and
T-lymphocytes into the lung parenchyma in sensitized
guinea pigs (14). Interestingly, a remarkable steroid spar-
ing e¡ect of TJ-96 was noted within 6^12 months of
treatment in steroid-dependent asthmatic patients (15,
16). TJ-96 spared the downregulation of glucocorticoid
receptor of human lymphocytes, plasmaACTH, and cor-
tisol levels. It also spared downregulation of b2 receptor
by b2 agonists and suppressed mACh receptor at the
same time. Furthermore, TJ-96 inhibited the induction
of expression of IgE-FcP R/CD23 by mite allergen in the
lymphocytes of the patients with mite-allergic asthma
(15). Nakajima et al. showed TJ-96 inhibited IgE produc-
tion by mite allergens, and decreased the number of eo-
sinophils in the bronchoalveolar lavage £uid during late
asthmatic response. These ¢ndings suggest that TJ-96
may be e¡ective in inhibiting both the expression of IgE-
FcPR2 and the induction of expression of IgE-FcPR1. Also,
it has been reported that TJ-96 also has a steroid-like ac-
tion and polyhedral antiasthmatic activities (16). In vitro,
TJ-96 modulates basophil growth and di¡erentiation
(17), eosinophilic in¢ltration (3), platelet-activating factor
production in human neutrophils (18), and histamine re-
lease frommast cells (19). Konno et al. reported that TJ-
96 selectively stimulates Na absorption across the tra-
cheal epithelium through intracellular accumulation of
cyclic AMP and NO generation (20,21). Moreover, it has
been reported that TJ-96 inhibits 5-lipoxy genase activ-
ity in leukotriene synthesis in rat basophilic leukemia-1
cells (22).These properties indicate that TJ-96 can mod-
ulate immune responses both in vitro and in vivo.
Some previous reports suggested that one of the ac-
tive ingredients of TJ-96, magnolol might contribute to
the antiasthmatic e¡ects and the inhibitory e¡ects on
prednisolone metabolism through inhibition of 1lb-hy-
droxy steroid dehydrogenase (23^25).Magnolol, isolated
from Magnolia o⁄cinalis, has anti-in£ammatory e¡ect,
reversedpassiveArthusreaction (26), and inhibits leuko-
triene release from basophils (27).To determine the ex-
act mechanisms of antiasthmatic e¡ect of TJ-96,
additional studies will be required.
In this study, our results provide clinical support for
theseprevious investigations.This studyraises further in-
teresting therapeutic possibilities and supports the usefor further trials of new approaches to the treatment of
asthma.
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